Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | PI4KA | P42356 | 1/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065802 | 0.76 | CYP1A2 (0.49) | GPR3EGFRLMNA | |
| SCHEMBL5392739 | 0.74 | LMNA (0.46) | GPR3LMNAHTTADORA2A | |
| SCHEMBL17048132 | 0.72 | METAP2 (0.41) | GPR3 | |
| SCHEMBL299834 | 0.70 | NPC1 (0.42) | GPR3LMNAADORA2A | |
| SCHEMBL16062228 | 0.69 | PDPK1 (0.43) | GPR3ADORA2A | |
| SCHEMBL4574523 | 0.68 | RAB9A (0.42) | GPR3LMNA | |
| SCHEMBL1725498 | 0.68 | DHODH (0.40) | GPR3 | |
| SCHEMBL317014 | 0.67 | GPR3 (0.41) | GPR3LMNA | |
| SCHEMBL16222851 | 0.66 | TNF (0.53) | LMNAHTT | |
| SCHEMBL1854776 | 0.66 | GPR3 (0.48) | GPR3LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1545512-B1 | Gold (III) complexes as anti-tumor and anti-HIV agents | UNIV HONG KONG (CN) | 2013-03-20 | — | — | EP | disclosed |
| EP-1545512-A4 | METHODS FOR USING GOLD (III) COMPLEXES AS ANTI-TUMOR AND ANTI-HIV AGENTS | UNIV HONG KONG (CN) | 2008-07-02 | — | — | EP | disclosed |
| EP-1545512-A1 | METHODS FOR USING GOLD (III) COMPLEXES AS ANTI-TUMOR AND ANTI-HIV AGENTS | The University of Hong Kong (CN) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005035500-A2 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 2005-04-21 | — | — | WO | disclosed |
| US-20040063681-A1 | Methods for using gold (III) complexes as anti-tumor and anti-HIV agents | CHE CHI-MING (CN) | 2004-04-01 | — | — | US | disclosed |
| WO-2004024146-A1 | METHODS FOR USING GOLD (III) COMPLEXES AS ANTI-TUMOR AND ANTI-HIV AGENTS | THE UNIVERSITY OF HONG KONG (CN) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063681-A1 | Methods for using gold (III) complexes as anti-tumor and anti-HIV agents | HCCS, ME3, IDH1 | GPR3 2724/4885EGFR 3563/4885PI4KA 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.